Valuation Protagonist Therapeutics, Inc.
Equities
PTGX
US74366E1029
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.87 USD | -2.31% |
|
-9.77% | +29.20% |
| 07-07 | Protagonist Therapeutics, Inc. - Special Call | |
| 06-17 | Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target | MT |
Company Valuation: Protagonist Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 867.3 | 1,632 | 536.8 | 1,323 | 2,300 | 3,091 | - | - |
| Change | - | 88.21% | -67.12% | 146.4% | 73.94% | 34.36% | - | - |
| Enterprise Value (EV) 1 | 561.4 | 1,305 | 411 | 1,136 | 2,203 | 2,974 | 2,828 | 2,915 |
| Change | - | 132.51% | -68.51% | 176.35% | 93.98% | 35% | -4.94% | 3.11% |
| P/E ratio | -10.5x | -12.6x | -4.2x | -16.5x | 9.13x | -28.4x | -118x | -44.7x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.3x | 1.03x | 0.4x | -0x | 0x | 1.6x | -0x |
| Capitalization / Revenue | 30.3x | 59.7x | 20.2x | 22x | 5.3x | 38x | 17.3x | 22.3x |
| EV / Revenue | 19.6x | 47.7x | 15.5x | 18.9x | 5.07x | 36.6x | 15.8x | 21x |
| EV / EBITDA | -8.81x | -10.4x | - | -12.3x | 8.69x | -20.8x | 105x | -85.9x |
| EV / EBIT | -8.7x | -10.4x | -3.13x | -12.1x | 8.71x | -25.6x | -219x | -41.4x |
| EV / FCF | -7.7x | -12x | -3.77x | -16x | 12.1x | -127x | 29.8x | -583x |
| FCF Yield | -13% | -8.35% | -26.5% | -6.24% | 8.3% | -0.78% | 3.36% | -0.17% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.92 | -2.71 | -2.6 | -1.39 | 4.23 | -1.758 | -0.4211 | -1.116 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 28.63 | 27.36 | 26.58 | 60 | 434.4 | 81.31 | 179 | 138.9 |
| EBITDA 1 | -63.73 | -125 | - | -92.68 | 253.7 | -143.3 | 27.04 | -33.94 |
| EBIT 1 | -64.52 | -125.8 | -131.4 | -93.65 | 252.8 | -116.4 | -12.89 | -70.43 |
| Net income 1 | -66.15 | -125.6 | -127.4 | -78.96 | 275.2 | -112.4 | 8.673 | -75.84 |
| Net Debt 1 | -305.8 | -326.9 | -125.7 | -186.7 | -97.25 | -116.7 | -263.5 | -175.6 |
| Reference price 2 | 20.16 | 34.20 | 10.91 | 22.93 | 38.60 | 49.87 | 49.87 | 49.87 |
| Nbr of stocks (in thousands) | 43,019 | 47,728 | 49,198 | 57,678 | 59,598 | 61,982 | - | - |
| Announcement Date | 3/10/21 | 2/28/22 | 3/15/23 | 2/27/24 | 2/21/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -28.38x | 36.58x | -20.76x | - | 3.09B | ||
| 38.52x | 5.61x | 19.69x | 0.88% | 49.47B | ||
| 46.5x | 9.42x | 27.85x | 0.4% | 28.87B | ||
| 150.55x | 5.17x | 88.72x | -.--% | 28.55B | ||
| 21.74x | 2.52x | 10.71x | -.--% | 28.1B | ||
| 22.57x | 1.92x | 8.71x | 1.15% | 12.68B | ||
| 15.86x | 1.8x | 9.06x | -.--% | 11.73B | ||
| -41.39x | 15.31x | -47.96x | -.--% | 10.66B | ||
| 24.78x | 5.17x | 13.75x | 0.11% | 10.29B | ||
| -38.23x | 8.51x | 1970.82x | -.--% | 10.04B | ||
| Average | 21.25x | 9.20x | 208.06x | 0.28% | 19.35B | |
| Weighted average by Cap. | 41.20x | 6.35x | 125.01x | 0.37% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- PTGX Stock
- Valuation Protagonist Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition